Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Evanston, Illinois Clear all
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

NCT03308968
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty

NCT01990820
View directory record Official record
Conditions
Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis
Interventions
Acclarent Relieva Balloon Sinuplasty, Adenoidectomy + Maxillary Sinus Irrigation
Device · Procedure
Lead sponsor
Endeavor Health
Other
Eligibility
2 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated No phase listed Observational

Connect® Myeloid Disease Registry

NCT01688011
View directory record Official record
Conditions
Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
155
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prenatal Sonographic Prediction of Placental Histology and Function

NCT06022458
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Not listed
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

NCT02544633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
84
States / cities
Birmingham, Alabama • Coronado, California • Lancaster, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00049348
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
epoetin alfa, filgrastim, cisplatin, fluorouracil, gemcitabine hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
137
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boca Raton, Florida + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 7, 2026, 4:59 AM EDT
Active, not recruiting Not applicable Interventional

A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels

NCT04564885
View directory record Official record
Conditions
Cervical Disc Disease
Interventions
BAGUERA®C Cervical Disc Prosthesis, Mobi-C Cervical Disc
Device
Lead sponsor
Spineart USA
Industry
Eligibility
22 Years to 69 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206
View directory record Official record
Conditions
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions
zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
503
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

NCT03749447
View directory record Official record
Conditions
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Active, not recruiting Not applicable Interventional

Patient Outcomes Collection: How Can we do Better?

NCT03653455
View directory record Official record
Conditions
Shoulder Pain
Interventions
Email reminders, Pre- and Post-operative discussion, Incentive
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Completed No phase listed Observational Results available

PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure

NCT00279955
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Cardiac Resynchronization Therapy Device
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
93
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT04034485
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
lerodalcibep, evolocumab
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00003352
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Taxotere, Adriamycin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
152
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834
View directory record Official record
Conditions
Melanoma
Interventions
Elesclomol (STA-4783), Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00022477
View directory record Official record
Conditions
Colorectal Cancer
Interventions
BMS-247550
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jun 7, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Not applicable Interventional Results available

The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position

NCT01546636
View directory record Official record
Conditions
Cerebral Ischemia
Interventions
Hypocapnic group, Normocapnic group
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 7, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 39 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jun 7, 2026, 4:59 AM EDT
Completed No phase listed Observational Results available

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

NCT01131104
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
PDE5 Inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Los Altos, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 7, 2026, 4:59 AM EDT